The Combination of the PARP Inhibitor Olaparib and the Wee1 Inhibitor AZD1775 As a New Therapeutic Option for Small Cell Lung Cancer
Author Manuscript Published OnlineFirst on June 25, 2018; DOI: 10.1158/1078-0432.CCR-17-2805 Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. The combination of the PARP inhibitor olaparib and the Wee1 inhibitor AZD1775 as a new therapeutic option for small cell lung cancer Alice Lallo1,*, Kristopher K Frese1,*, Christopher J Morrow1, Robert Sloane1, Sakshi Gulati1, Maximillian W Schenk1, Francesca Trapani1, Nicole Simms1, Melanie Galvin1, Stewart Brown1, Cassandra L Hodgkinson1, Lynsey Priest1, Adina Hughes4, Zhongwu Lai5, Elaine Cadogan4, Garima Khandelwal3, Kathryn L Simpson1, Crispin Miller3, Fiona Blackhall2, Mark J O’Connor4,#, and Caroline Dive1,# 1 Clinical and Experimental Pharmacology Group, Cancer Research UK Manchester Institute, University of Manchester, Manchester, M20 4BX, UK. 2 Institute of Cancer Sciences, University of Manchester, Manchester, United Kingdom. Christie NHS Foundation Trust, Manchester, M20 4BX, UK. 3 RNA Biology Group, Cancer Research UK Manchester Institute, University of Manchester, Manchester, M20 4BX, UK. 4 Oncology Innovative Medicines and Early Development Biotech Unit, AstraZeneca, Cambridge, CB2 0RE, UK. 5 Oncology Innovative Medicines and Early Development Biotech Unit, AstraZeneca, Waltham, 02451, USA. *These authors contributed equally to this work Running title: PARP and Wee1 inhibition in patient-derived models of SCLC C. Dive receives funding from the Cancer Research UK Manchester Institute core (C5759/A27412), the Cancer Research UK Manchester
[Show full text]